{"contentid": 488125, "importid": NaN, "name": "US regulator approves expanded label for Keytruda", "introduction": "The US Food and Drug Administration has approved a label update for Merck & Co\u00e2\u0080\u0099s blockbuster checkpoint blocker, targeting advanced esophageal or gastroesophageal (GEJ) cancer.", "content": "<p>The US Food and Drug Administration has approved a label update for Merck &amp; Co&rsquo;s (NYSE: MRK) blockbuster checkpoint blocker, targeting advanced esophageal or gastroesophageal (GEJ) cancer.</p>\n<p>Keytruda (pembrolizumab), which took in $14.4 billion sales for the New Jersey, USA-based firm last year, can now be offered for certain people with metastatic or locally advanced GEJ, in combination with chemotherapy.</p>\n<p>The decision was made based on data from the KEYNOTE-590 trial, which showed a statistically-significant improvement in overall survival (OS) and progression-free survival (PFS).</p>\n<p>Median OS was 12.4 months for the test group, versus 9.8 months for placebo. Median PFS was 6.3 months and 5.8 months.</p>\n<h2>Rapid review</h2>\n<p>While the FDA already has a wealth of data on Keytruda to help guide its decision-making, the regulator&rsquo;s latest verdict on the immunotherapeutic was still impressive for its alacrity, coming a full three weeks ahead of the target date.</p>\n<p>This was made possible in part because of the Real-Time Oncology Review (RTOR) pilot program, which streamlined data submission prior to filing.</p>\n<p>The review was also conducted under Project Orbis, an initiative which provides a framework for concurrent submission and review of oncology drugs among international partners.</p>\n<p>For this review, the US FDA collaborated with the Australian Therapeutic Goods Administration (TGA), Health Canada, and Switzerland&rsquo;s Swissmedic, all of which are yet to deliver a verdict on the submission.</p>", "date": "2021-03-23 13:50:00", "meta_title": NaN, "meta_keywords": "label, Keytruda, advanced, months, Administration, review, approves, regulator, expanded, approved, Drug, Food, update, esophageal, gastroesophageal, Merck", "meta_description": "The US Food and Drug Administration has approved a label update for Merck & Co\u00e2\u0080\u0099s blockbuster checkpoint blocker, targeting advanced esophageal or gastroesophage", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-23 13:39:49", "updated": "2021-03-23 13:51:42", "access": NaN, "url": "https://www.thepharmaletter.com/article/us-regulator-approves-expanded-label-for-keytruda", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "keytruda_big.png", "image2id": "keytruda_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Immuno-oncology", "topic_tag": "Drug Trial, Focus On, Regulation, Research, US FDA", "geography_tag": "USA", "company_tag": "Merck & Co", "drug_tag": "Keytruda", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-23 13:50:00"}